| Active substance | Tolvaptan |
| Holder | Otsuka Pharmaceutical Development and Commercialization, Inc |
| Status | Running |
| Indication | Treatment of Children and Adolescent Patients until they reach 18 years of age with Autosomal Dominant Polycystic Kidney Disease Following Successful Participation and Completion in the 156-12-298 Clinical Trial |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/08/2022 |